Eticovo® (etanercept-ykro)

aBL 761066

Eticovo® (etanercept-ykro)

aBL 761066

U.S. License Holder:

Samsung Bioepis Co. Ltd.

Date of License:


Last Update:


approved_indications FDA-Approved Indications

ETICOVO (etanercept-ykro) is a tumor necrosis factor (TNF) blocker indicated for the treatment of Adult patients with:

Rheumatoid Arthritis (RA);

Psoriatic Arthritis (PsA);

Ankylosing Spondylitis (AS);

Plaque Psoriasis (PsO);

Pediatric patients with:

Polyarticular Juvenile Idiopathic Arthritis (JIA) 2 years of age or older;

Plaque Psoriasis (PsO) 4 years of age or older.

approved_indications Approved Foreign Follow-On Biologics / Biosimilars

Biosimilars Approved In Canada

Brenzys (Samsung Bioepis / Merck Canada) (August-2016)

Biosimilars Approved In The E.U.

Benepali (Samsung Bioepis / Biogen) (January-2016)

Biosimilars Approved In Australia

Brenzys (Samsung Bioepis) (July-2016)

Biosimilars Approved In South Korea

Etoloce (Samsung Bioepis) (September-2015)

approved_indications U.S. Patent Litigations


Case No(s):

U.S. Patent Nos.
7,915,225 (Soluble Tumor Necrosis Factor Receptor Treatment of Medical Disorders) 8,063,182 (Human TNF Receptor Fusion Protein) 8,119,605 (Soluble Tumor Necrosis Factor Receptor Treatment of Medical Disorders) 8,163,522 (Human TNF Receptor) 8,722,631 (Soluble Tumor Necrosis Factor Receptor Treatment of Medical Disorders)

Amgen Manufacturing, Ltd.; Hoffmann-La Roche Inc.; Immunex Corp.

Samsung Bioepis Co., Ltd.; Intervenors: Sandoz GmbH; Sandoz, Inc.; Sandoz International GmbH

Stipulation of Infringement of '182 and '522 Patents, Final Judgment Entered in Favor of Plaintiffs and Permanent Injunction Issued



Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website ( Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website ( Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.


The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates